RT Journal Article
T1 Seroreversion of IgG anti-HEV in HIV cirrhotic patients: A long-term multi-sampling longitudinal study.
A1 Lopez-Lopez, Pedro
A1 Frias, Mario
A1 Camacho, Angela
A1 Machuca, Isabel
A1 Caballero-Gomez, Javier
A1 Risalde, Maria A
A1 Garcia-Bocanegra, Ignacio
A1 Perez-Valero, Ignacio
A1 Gomez-Villamandos, Jose C
A1 Rivero-Juarez, Antonio
A1 Rivero, Antonio
K1 HCV
K1 HEV
K1 HIV
K1 Antibodies
K1 Cirrhotic
K1 Seroreversion
AB The aim of our study was to evaluate HEV antibody kinetics in HIV/HCV-coinfected patients with cirrhosis. A longitudinal retrospective study was designed. Patients were followed up every 6 months; anti-HEV IgG and IgM antibodies levels and HEV-RNA by qPCR were analysed. The prevalence and incidence of every HEV infection marker were calculated. The kinetics of anti-HEV IgG and IgM during the follow-up were evaluated. Seventy-five patients comprised the study population. The seroprevalence observed was 17.3%. None showed IgM antibodies or HEV-RNA at baseline. None showed detectable HEV viral load during the study period. After a median follow-up of 5.1 years, two of 62 seronegative patients (3.2%) seroconverted to IgG antibody. The incidence for IgM was 2.7%. Of the 13 patients with IgG seropositivity at baseline, five (38.5%) seroreverted. Meanwhile, of the two patients who exhibited IgM positivity during the study, one (50%) showed intermittent positivity. We found that HEV seropositivity is common in HIV/HCV-coinfected cirrhotic patients. A remarkable rate of IgG seroreversions and IgM intermittence was found, limiting the use of antibodies for the diagnosis of HEV infection in this population.
PB Wiley
YR 2022
FD 2022-02-17
LK http://hdl.handle.net/10668/20022
UL http://hdl.handle.net/10668/20022
LA en
NO López-López P, Frias M, Camacho A, Machuca I, Caballero-Gómez J, Risalde MA,  et al. Seroreversion of IgG anti-HEV in HIV cirrhotic patients: A long-term multi-sampling longitudinal study. Transbound Emerg Dis. 2022 Sep;69(5):e1541-e1548
DS RISalud
RD Apr 9, 2025